openPR Logo
Press release

Non Melanoma Skin Cancer Market Expected To Reach $24.3 Billion By 2031 | Merck and Co Inc, Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH

11-18-2024 08:27 AM CET | Health & Medicine

Press release from: DataM Intelligence 4 Market Research LLP

Non Melanoma Skin Cancer Market || 2024-2031

Non Melanoma Skin Cancer Market || 2024-2031

The Non Melanoma Skin Cancer Market study by DataM Intelligence offer an in-depth analysis of the market, presenting insightful observations, statistics, historical data, and industry-validated market insights. The report delves into the competitive positioning of key companies, examining factors such as product offerings, pricing strategies, financial health, product portfolios, growth initiatives, and geographical reach.

Download a Free sample PDF (Use Corporate email ID to Get Higher Priority) at: - https://datamintelligence.com/download-sample/non-melanoma-skin-cancer-market

What is the projected growth rate (CAGR) of the Global Non Melanoma Skin Cancer market from 2024 to 2031, and what is the market value expected to change by 2031?

The Global Non Melanoma Skin Cancer Market reached USD 645.7 million in 2022 and is projected to witness lucrative growth by reaching up to USD 911.9 million by 2031. The non melanoma skin cancer market is expected to exhibit a CAGR of 4.5% during the forecast period (2024-2031).

Non-melanoma skin cancer refers to a group of skin cancers that are not classified as melanoma, the deadliest form of skin cancer. The most common types of non-melanoma skin cancer are basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). These cancers typically develop in the epidermis, the outermost layer of skin, and are often caused by prolonged exposure to ultraviolet (UV) radiation from the sun or tanning beds. Non-melanoma skin cancers are generally less aggressive than melanoma and have a higher cure rate when detected early. However, they can still cause significant damage if left untreated.

Key Developments:

❁ In January 2023, an FDA submission was made for cosibelimab (formerly CK-301), an investigational anti-PD-L1 antibody, to treat patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or radiation.

❁ In May 2023, Almirall and the Centre for Genomic Regulation (CRG) announced a collaboration focused on non-melanoma skin cancer research. The partnership aims to develop innovative preclinical models to identify new treatments for non-melanoma skin cancer (NMSC).

❁ In March 2023, the FDA granted full approval to cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic basal cell carcinoma (BCC) who have previously received a hedgehog inhibitor (HHI). This approval followed a study involving 138 patients with locally advanced or metastatic, nodal, or distant BCC, who had either progressed on HHI, failed to respond after 9 months of therapy, or were intolerant to prior HHI treatment.

List of the Key Players in the Non Melanoma Skin Cancer Market:

Merck and Co Inc, Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH, Bristol Myers Squibb Company, Elekta AB, Eli Lilly and Company, F. Hoffmann La Roche AG and Novartis AG, Amgen

Research Process:

Both primary and secondary data sources have been used in the global Non Melanoma Skin Cancer Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Segment Covered in the Non Melanoma Skin Cancer Market:

By Treatment: Immunotherapy, Radiation Therapy, Chemotherapy, Photodynamic Therapy, Others

By Indication: Basal cell carcinoma, Squamous cell carcinoma, T Cell Lymphoma

By End-User: Hospitals, Ambulatory surgical centers, Speciality Clinics, Others

Regional Breakout:

The global Non Melanoma Skin Cancer Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

✫ North America (U.S., Canada, Mexico)

✫ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

✫ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

✫ South America (Colombia, Brazil, Argentina, Rest of South America)

✫ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Get Year End Discounts on Premium Report:- https://www.datamintelligence.com/buy-now-page?report=non-melanoma-skin-cancer-market

This Report Unveils:

✔ Go to Market Strategy- A roadmap to successfully product launch or service in the target market.

✔ Gain a clear picture of the market's health and growth trajectory through neutral analysis.

✔ Deep Market Insights delve into development trends, competitor landscape, supply and demand dynamics, brand share & pricing analysis year-over-year growth patterns, and key players' performance.

✔ Upon request, we can provide customized reports focusing on specific regions or countries, offering a granular view of their markets.

✔ Identify high-potential niche segments and regions poised for significant expansion.

✔ Analysis of Market Size (historical and forecast) Total Addressable Market (TAM), Serviceable Available Market (SAM), and Serviceable Obtainable Market (SOM) to understand the market's overall size and your achievable market share.

✔ Gain a comprehensive understanding of the competitive landscape, including market share distribution, key players (innovators, startups, laggards, and pioneers), and their respective strengths and weaknesses.

**The full version of the report includes an in-depth analysis of emerging players and startups, which will provide valuable insights into the evolving market landscape and key strategies being adopted**

Chapter Outline:

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: key insights, key emerging trends, etc.

Chapter 3: Manufacturers competitive analysis, detailed analysis of Non Melanoma Skin Cancer manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 5 & 6: Revenue of Non Melanoma Skin Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the Non Melanoma Skin Cancer market in different market segments.

Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the Non Melanoma Skin Cancer market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: The main points and conclusions of the report.

Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/non-melanoma-skin-cancer-market

Frequently Asked Questions

☞ What is the expected growth rate of the global Non Melanoma Skin Cancer market for the forecast period?

☞ What are the key driving factors that are responsible to shape the fate of the Non Melanoma Skin Cancer market during the forecast period?

☞ What will be the overall size of the market during the analysis period?

☞ What are the prominent market trends which influence the development of the Non Melanoma Skin Cancer market across various regions?

☞ Who are the key market players and the market strategies that have helped them to secure the leading position in the global market?

☞ What are the challenges and threats that are likely to act as a barrier to the growth of the Non Melanoma Skin Cancer market?

☞ What are the major opportunities that the companies can get to attain success in the world?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Non Melanoma Skin Cancer Market Expected To Reach $24.3 Billion By 2031 | Merck and Co Inc, Accuray Incorporated, Almirall S.A., Boehringer Ingelheim GmbH here

News-ID: 3740115 • Views:

More Releases from DataM Intelligence 4 Market Research LLP

United States Automatic Packaging Robot Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
United States Automatic Packaging Robot Market 2025 | Industry Developments, Fut …
Automatic Packaging Robot Market reached US$ 4.0 billion in 2023 and is projected to reach US$ 10.2 billion by 2031, growing at a CAGR of 12.4% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Automatic Packaging Robot Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and
Human Augmentation Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Human Augmentation Market 2025 | Industry Developments, Future Growth, Share & I …
The Human Augmentation Market reached US$ 252.6 billion in 2023 and is projected to reach US$ 780.7 billion by 2031, growing at a CAGR of 15.6% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Human Augmentation Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging
Learning Management System (LMS) Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Learning Management System (LMS) Market 2025 | Industry Developments, Future Gro …
Learning Management System (LMS) Market reached US$ 18.7 billion in 2023 and is projected to reach US$ 67.2 billion by 2031, growing at a CAGR of 17.7% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Learning Management System Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts,
Team Collaboration Tools Market 2025 | Industry Developments, Future Growth, Share & Industry Insights
Team Collaboration Tools Market 2025 | Industry Developments, Future Growth, Sha …
The Team Collaboration Tools Market reached US$ 23.3 billion in 2023 and is projected to reach US$ 62.8 billion by 2031, growing at a CAGR of 13.5% during the forecast period 2024-2031. DataM Intelligence unveils its latest report on the "Team Collaboration Tools Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts,

All 5 Releases


More Releases for Melanoma

Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period? The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market? The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market? The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma. Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379 Key Players Analysis: • Pfizer Inc. • Bristol-Myers Squibb Company • Abbott Laboratories • Amgen, Inc. • Merck & Co., Inc. • Novartis AG • F. Hoffmann-La Roche Ltd • Sanofi S.A. • Qiagen NV • Sun Pharmaceutical Industries Ltd
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic